



IAEA Phase III randomised trial

IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases



Peter Hoskin^a, Ana Rojas^{a,*}, Elena Fidarova^b, Rakesh Jalali^c, Ana Mena Merino^d, Adela Poitevin^e, Seam Oucrif^f, Sherif Abdelwahab^g, Lotfi Kochbati^h, Aista Plieskieneⁱ, Francesc Casas^j, Susana Stojanovic^k, Günther Schneider^l, Branislav Jeremic^b

^a Cancer Centre, Mount Vernon Hospital, UK; ^b IAEA, Division of Human Health, Vienna, Austria; ^c Tata Memorial Hospital, Mumbai, India; ^d Hospital Son Dureta, Palmas de Mallorca, Spain; ^e Instituto Nacional Cancerología, México DF, Mexico; ^f Dep. Radiothérapie, Centre Hospitalier Universitaire, Alger, Algeria; ^g Misr Oncology Centre, Cairo, Egypt; ^h Radiotherapie carcinologique, Institut Salah Azaiz, Tunis, Tunisia; ⁱ Institute of Oncology, Vilnius University, Lithuania; ^j Radiation Oncology, Hospital Clinic i Universitari, Barcelona, Spain; ^k Institute of Oncology & Radiology, Belgrade, Serbia; ^l Fundacao Faculdade Federal de Ciencias Medicas, Porto Alegre, Brazil

ARTICLE INFO

Article history:

Received 18 February 2015
Received in revised form 12 May 2015
Accepted 16 May 2015
Available online 27 May 2015

Keywords:

Bone metastases
Bone pain
Palliative radiotherapy
Dose response

ABSTRACT

Background: To determine the optimal single-dose radiotherapy schedule for pain from bone metastases in a multi-centre, international, randomised trial.

Patients and methods: 651 patients were randomised to either 8 Gy ($n = 325$) or 4 Gy ($n = 326$) radiotherapy. Pain at 4, 8, 12, 24 and 52 weeks was assessed using a Categorical Scale (CS) and a Visual Analogue Scale (VAS). The primary endpoint was response at 4 weeks.

Results: There was no significant difference in patient demographics and other co-variables. The complete response (CR) rate and ORR (complete or partial response) for all follow-up times were higher after 8 Gy ($p = 0.02$). The Kaplan–Meier actuarial rate (categorical scale) at 4 weeks for ORR was 80% after 8 Gy compared to 68% after 4 Gy ($p = 0.0015$). 117 re-treatments were given of which 72 were in the 4 Gy group and 45 in 8 Gy arm ($p = 0.01$).

Conclusions: There was a marked consistent difference in pain relief at all time points in favour of 8 Gy. These data reinforce the case for single dose 8 Gy radiotherapy to be recommended for metastatic bone pain in all healthcare settings.

© 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 116 (2015) 10–14

Bone metastases arise in up to 70% of all cancer patients and represent a major workload and cause of morbidity in cancer patients [1,2].

The pathogenesis of metastatic bone pain remains unclear [3,4]. Treatment of painful bone metastasis includes analgesics and adjuvant analgesics, bisphosphonates, surgery and nerve blocks, alongside anti-tumour therapy using endocrine therapy, chemotherapy, radiopharmaceuticals and beam radiotherapy (RT) [5]. RT is the mainstay of treatment for painful bone metastasis [6] accounting ~20% of the daily workload [7,8]. The mechanism of pain relief after RT is uncertain. Although the destruction of tumour cells followed by bone remodelling occurs, the rapid speed of onset and the maintenance of pain relief post-RT and absence of a dose response suggest that tumour cell kill is not the only factor. Other possible mechanisms include an effect on sensitive host cells producing pain mediators, direct effect on osteoclast activity, or

disturbance of the neuronal transmission of pain. There is also likely to be a placebo effect [5].

Single dose treatments (8–10 Gy) are as effective as multifraction regimens (20–30 Gy in 5 to 10 daily treatments) and class 1 evidence comes from randomized trials and meta-analyses [9,10]. The optimal single dose of RT required for pain relief is unknown. Two studies have shown that 8 Gy yields better pain relief than 4 Gy, however, 4 Gy was effective in a large proportion of patients [11,12]. With 8 Gy overall response rates of 70–85% were observed compared to 43–59% after a single fraction of 4 Gy.

This IAEA sponsored multi-centre, international, randomised trial was undertaken to further explore the optimal single radiation dose for metastatic bone pain in a range of healthcare settings.

Patients and methods

Patients aged 18 years or more, with a histological diagnosis of malignancy, radiological evidence of painful bone metastasis and a life expectancy of 12 weeks or more were eligible for randomisation into the study. For patients with two sites of pain requiring

* Corresponding author at: Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK.

E-mail address: arc03@btconnect.com (A. Rojas).

separate treatment the same randomized treatment option was used for both sites, but response at each site was scored and analysed separately.

Institutional board review and informed consent in keeping with local and national regulatory practice was mandatory. Exclusion criteria were primary histology myeloma, bone metastasis in sites previously irradiated, previous radioisotope treatment, conditions or circumstances that may impede treatment or follow-up, and patients with complicated bone metastasis (pathological fractures, metastatic spinal cord compression).

At baseline all patients underwent a physical examination (including neurological examination), full blood count and biochemical screen, required within 7 days of randomisation. Randomisation was by fax of a registration form to the Central Trials Office confirming entry criteria returned within 24 h.

Patients were stratified according to single versus multiple bone metastasis, histology, and participating centre and randomised 1:1 to one of the following groups:

Group A: patients with a single site of bone pain to be treated.

Group B: patients with multiple sites of bone pain.

The randomization in group A was between a single dose of 8 Gy and a single dose of 4 Gy and in group B between a single dose of 8 Gy and 12 Gy in 4 fractions of 3 Gy given in 2 consecutive days with a minimum interfraction interval of 6 h.

Radiotherapy was delivered with megavoltage equipment with minimum nominal energy of 1.25 MeV. Single, direct (posterior) fields or parallel opposed fields technique was used to treat spinal metastasis, direct field or tangential fields for rib metastasis and two parallel opposed fields to treat pelvis, hip or long bones. The prescribed dose was to the 100% isodose with single fields, the central (mid-plane) dose for opposed fields and at depth for vertebrae defined at the centre of the vertebral body or 5 cm depth if this was not measured.

The treatment field encompassed a 2 cm margin on each side of the bone metastasis. For the spine fields at least one vertebra above and below the affected vertebrae were included. Any soft tissue extension of tumour was covered by a 2 cm margin.

All patients were simulated before irradiation. Verification (portal) films on the treatment machine were optional.

Re-treatment with 8 Gy was given to the initially treated site if moderate or severe pain persisted or recurred at 4 weeks or more after initial radiotherapy. A second re-treatment (≥ 4 weeks after first re-treatment) could be given using the same criteria as first re-treatment.

Analgesic use was scored at baseline and at each follow up.

Endpoints and statistical analysis

The primary endpoint was the difference in the proportion of responders at 4 weeks from randomization. The study was powered to detect a 10% lower response rate in the experimental arms of each group with a two-sided p test where $\alpha = 0.05$ and $1 - \beta = 0.8$. Allowing for an attrition rate of 10%, a target sample size of 320 patients was defined for each arm, totalling 1280 patients.

A four-point categorical scale (CS) – none, mild, moderate or severe – and a 10 cm visual analogue scale (VAS) were used to measure pain. Patients were assessed at randomisation (baseline), at four, eight, twelve, twenty-four and fifty-two weeks after randomisation. A complete response (CR) was defined by no pain on the CS and a score of zero on VAS and partial response (PR) by an improvement by at least one category of pain (e.g. from moderate to mild) or a reduction in the VAS score of at least 10 mm. No response (NR) was defined by no change in pain category or a

change of <10 mm on the VAS. Pain relief was also scored incorporating analgesic requirements to provide “combined pain relief” using a categorical scale (0 = none; 1 = non-opiates; 2 = weak opiates; 3 = strong opiates). CR was defined as total absence of pain; PR was an improvement by at least one pain category with either no analgesics or decreased or stable analgesics. Progression of pain was defined as an increase in the pain score by at least one category with analgesics either stable or increased or stable pain score with analgesics increased.

Statistical comparisons were carried out using JMP™, SAS Institute, Cary, NC, USA. Differences in patients’ baseline demographics and treatment features were compared using χ^2 and Kruskal–Wallis tests for categorical and continuous covariates, respectively. Analyses were performed as per protocol with time to event calculated from day of randomisation. Response rates (RR) were calculated by dividing the number of patients who responded at a defined time point by the total population in the study (prevalence). A “best case” actuarial response rate was calculated using the Kaplan–Meier method and differences compared with the Mantel–Cox log-rank test. Prevalence was calculated using the actual number of patients seen at the particular follow-up and a χ^2 test used to compare differences between dose groups. Where appropriate, the defined level of significance was adjusted using Bonferroni’s correction method for multiple comparisons.

Results

Between 22 January 2008 and 31 August 2012, 655 patients were randomised into Group A: 326 into Arm 1 and 325 into Arm 2 (see Consort diagram Fig. 1). Accrual into Group B (arms 3 and 4) of the trial was poor and only 40 patients were entered into Arm 3 and 30 to Arm 4 at the time of study closure. Therefore, only results for Group A have been analysed and are presented here.

Table 1 summarises the site treated and the primary tumours; these are well balanced. Table 2 gives demographic features and other co-variables.

Crude incidence (all follow-ups) and prevalence of pain relief at 4 weeks (primary endpoint) are shown in Table 3. Using the CS, there was a small but significant difference in favour of 8 Gy in the global comparison for all follow-up times and the number of complete responders was higher for those treated with 8 Gy compared to 4 Gy, although significant only at 8 weeks ($p = 0.03$). The ORR (overall response rate) was significantly higher for the 8 Gy dose group at the two time points shown in Table 3 and maintained at 8 and 52 weeks ($p = 0.03$). Using the VAS method rather than the CS, there is a reduction in the number of complete responders in both dose groups, but overall incidence and 4-week prevalence remain significantly higher after 8 Gy.

The actuarial rate (CS) at 4 weeks, calculated using the Kaplan–Meier method, showed a significant difference in ORR of 80% after 8 Gy compared to 68% after 4 Gy ($p = 0.0015$) but no difference in CR (32% vs 34%).

Combined pain relief is shown in Table 4. The difference between dose groups was highly significant if a global comparison was made for all follow-up times. Prevalence of complete responders at 4 weeks using the CS was significantly higher for patients treated with 8 Gy and this was maintained between 8 weeks and 52 weeks, although significant only at 8 weeks ($p = 0.0005$). The proportion of partial responders was similar at all follow-up times. The VAS method detected a significant difference in favour of 8 Gy only for complete responders assessed 4 weeks after randomisation.

A total of 117 retreatments were given; 72 after 4 Gy and 45 after 8 Gy ($p = 0.01$).




Fig. 1. Consort flow diagram

Discussion

This trial differs from previous studies having a larger contribution of lung cancer patients and a relatively low proportion of prostate cancer patients reflecting the inclusion of centres where prostate cancer is at present relatively low in incidence [10]. Despite this the results are similar to those from other studies delivering 8 Gy as a single dose with overall responses seen in 70–80% patients at four weeks and a complete response rate of 33–35% [11–15]. However the response after 4 Gy is still 71% when the categorical scale is used and 82% when the VAS is used. This is in contrast to the other two studies which have looked at this question, where the 4 Gy arm overall response rate was much lower at 45–59% [11,12].

The international consensus on bone pain and radiotherapy has defined clear criteria for response using both pain score and analgesic use [16,17]. When this score is used the response rate using the categorical scale falls to 57% after 8 Gy and 45% after 4 Gy, the latter being closer to that reported elsewhere for this dose schedule. Using the VAS the combined score gives a higher overall score of 71% after 8 Gy and 72% after 4 Gy. Pain score methodology therefore has a major impact on the measured levels of pain relief. The VAS is in principle more sensitive to subtle changes in effect, a response reflecting a 10% change on a continuous scale whilst the categorical scale works on 25% increments.

Although the overall response after 4 Gy is considerable there is a clear difference in both quality and duration of pain relief. There is a consistent difference in complete response rates, the global analysis of pain relief at all time points is in favour of 8 Gy and the re-treatment rate was roughly double in the 4 Gy arm.

Table 1
Anatomical site of bone metastases and primary tumours.

Bone metastasis	4 Gy	8 Gy
Spine (primarily lumbar & dorsal)	131 40%	134 41%
Pelvis alone or +hip; + femur; + lumbar spine	72 22%	71 22%
Hip, femur or hip & femur	52 16%	49 15%
Humerus	15 5%	15 5%
Other	56 17%	56 17%
Primary	4 Gy	8 Gy
Breast	121 37%	109 34%
Lung	117 36%	109 34%
Prostate	53 16%	59 18%
Gastrointestinal	10 3%	20 6%
Kidney	3 1%	8 2%
Head & Neck	7 2%	8 2%
Bladder	7 2%	6 2%
Endometrium	1 0.3%	1 0.3%
Other	7 2%	5 2%

Table 2
Demographic features, baseline conditions and other treatment details for patients randomised to Group A.

Variable	Category	4 Gy n = 326	8 Gy n = 325	p
Age(years)	Median	56	58	0.1
	Range	25–87	25–88	
Analgesics	None	60 (19%)	70 (22%)	0.3
	Non opiates	73 (23%)	72 (23%)	1
	Weak opiates	84 (27%)	83 (27%)	1
	Strong opiates	97 (31%)	88 (28%)	0.5
Pain at baseline(Categorical Scale)	No	1 (0.3%)	1 (0.3%)	1
	Mild	45 (14%)	43 (14%)	0.9
	Moderate	134 (43%)	141 (45%)	0.6
	Severe	134 (43%)	127 (41%)	0.6
Pain at baseline(VAS)	Median (cm)	6.7	6.9	0.6
	Range (cm)	0–10.6	0.4–10.2	
Chemotherapy	No	192 (62%)	206 (65%)	0.3
	Yes	119 (38%)	109 (35%)	
Hormone therapy	No	235 (76%)	224 (71%)	0.2
	Yes	74 (24%)	90 (29%)	
Bisphosphonates	No	206 (66%)	196 (62%)	0.3
	Yes	105 (34%)	119 (38%)	

Table 3
Incidence (all follow-ups) and prevalence at 4, 8 and 52 weeks of response to pain for patients with complete (CR), partial (PR), no (NR) and overall response (OR) using the categorical (CS) and visual analogue (VAS) scales.

CS	CR	p	PR	p	NR	p	OR	p
<i>All FUs</i>								
4 Gy	399 (48%)	0.02	269 (32%)	0.3	170 (21%)	<0.0001	668 (80%)	<0.0001
8 Gy	507 (53%)		330 (35%)		115 (12%)		837 (88%)	
<i>Week 4</i>								
4 Gy	87 (33%)	0.8	99 (38%)	0.02	74 (28%)	<0.002	186 (71%)	<0.002
8 Gy	95 (35%)		132 (48%)		47 (17%)		227 (83%)	
<i>Week 8</i>								
4 Gy	90 (46%)	0.03	74 (38%)	0.5	33 (17%)	<0.03	164 (83%)	<0.03
8 Gy	123 (56%)		75 (34%)		20 (9%)		198 (91%)	
<i>Week 52</i>								
4 Gy	54 (68%)	0.2	11 (14%)	0.7	14 (18%)	0.03	65 (82%)	0.03
8 Gy	77 (76%)		17 (17%)		7 (7%)		94 (93%)	
<i>VAS</i>								
<i>All FUs</i>								
4 Gy	69 (8%)	0.05	648 (78%)	0.6	119 (14%)	0.01	717 (86%)	0.01
8 Gy	104 (11%)		744 (79%)		98 (10%)		848 (90%)	
<i>Week 4</i>								
4 Gy	10 (4%)	0.006	203 (78%)	0.6	47 (18%)	0.2	213 (82%)	0.2
8 Gy	28 (10%)		209 (76%)		38 (14%)		237 (86%)	
<i>Week 8</i>								
4 Gy	15 (8%)	0.5	153 (78%)	0.5	28 (14%)	0.1	168 (86%)	0.1
8 Gy	21 (10%)		175 (81%)		20 (9%)		196 (91%)	
<i>Week 52</i>								
4 Gy	13 (17%)	1	52 (67%)	0.2	13 (17%)	<0.03	65 (83%)	<0.03
8 Gy	17 (17%)		76 (77%)		6 (6%)		93 (94%)	

FUs: follow-ups.

However the retreatment rate of 14% in the 8 Gy arm is low compared to others published where a rate of around 25% is found [18]. This may be because clear criteria for re-treatment were defined in the protocol unlike older randomized trials using this dose. Alternatively it may reflect individual clinician preferences with a lower threshold to consider re-treatment after only 4 Gy.

It remains remarkable that improvement of metastatic bone pain can be achieved in half to three quarters of patients after only 4 Gy. This observation has previously been used to support the view that pain response in bone metastases does not require significant tumour shrinkage although in most solid tumours, even those

relatively radio resistant, a large number of cells will be damaged and rendered non-viable by such a dose. This would reduce the chemotactic output from the tumour, which may be important in stimulating the large pain fibres that account for metastatic bone pain. An impact on host cells such as osteoclasts and on neural transmission has also previously been proposed and there is some limited evidence to support this [19,20].

This randomized trial was designed to explore the dose response for bone pain to single dose radiotherapy with sponsorship from the IAEA in a range of health care settings. It demonstrates that this treatment can be delivered effectively regardless

Table 4

Combined pain relief for complete responders (CR)¹ and partial responders (PR)² using the categorical scale (CS) and visual analogue scales (VAS) of pain measurement.

CS	CR	<i>p</i>	PR	<i>p</i>
<i>All follow-ups</i>				
Arm 1: 4 Gy	145 (17%)	<0.0001	242 (29%)	0.5
Arm 2: 8 Gy	251 (26%)		289 (31%)	
<i>Week 4</i>				
Arm 1: 4 Gy	24 (9%)	<0.04	93 (36%)	0.2
Arm 2: 8 Gy	43 (16%)		111 (41%)	
<i>Week 8</i>				
Arm 1: 4 Gy	22 (11%)	0.0005	63 (32%)	1
Arm 2: 8 Gy	53 (24%)		69 (32%)	
<i>Week 52</i>				
Arm 1: 4 Gy	35 (44%)	0.5	11 (14%)	1
Arm 2: 8 Gy	50 (50%)		15 (15%)	
<i>VAS</i>				
<i>All follow-ups</i>				
Arm 1: 4 Gy	40 (5%)	0.2	582 (70%)	0.4
Arm 2: 8 Gy	61 (7%)		676 (72%)	
<i>Week 4</i>				
Arm 1: 4 Gy	5 (2%)	0.02	180 (70%)	0.3
Arm 2: 8 Gy	16 (6%)		178 (65%)	
<i>Week 8</i>				
Arm 1: 4 Gy	6 (3%)	0.2	138 (71%)	0.2
Arm 2: 8 Gy	12 (6%)		166 (77%)	
<i>Week 52</i>				
Arm 1: 4 Gy	10 (13%)	0.8	49 (63%)	0.3
Arm 2: 8 Gy	11 (11%)		71 (72%)	

CR¹: no pain and no analgesics; PR²: improvement by at least one pain category with no, decreased or stable analgesics, when compared to previous follow-up.

of the socioeconomic setting. Limitations of the study include the fact that two thirds of patients were entered by two of the participating centres, albeit representing two different health care and cultural settings. The relatively low incidence of prostate cancer patients has been noted. In other studies these have not responded differently to other histological subtypes and it is unlikely therefore that this invalidates the results.

The results of this trial underline the role of radiotherapy in metastatic bone pain and argue strongly for single doses to be widely promoted with particular global benefits where resources are scarce. 8 Gy is optimal achieving a statistically significant higher likelihood of overall and complete response, which is sufficiently large to be clinically significant also. However 4 Gy is effective in a substantial proportion of patients and should be considered for those having re-treatment where tolerance doses are close or where there is concern over toxicity.

Conflicts of interest statement

No potential conflict of interests.

Acknowledgments

Funded by the International Atomic Energy Agency, Austria. The funding body had no role in the analysis, interpretation of the data,

in the writing of the report, or in the decision to submit the paper for publication.

References

- [1] Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. *Cancer* 2007;109:2334–42.
- [2] Li S, Peng Y, Weinhandl ED, Blaes AH, Cetin K, Chia VM, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. *Clin Epidemiol* 2012;4:87–93.
- [3] Haegerstam GA. Pathophysiology of bone pain: a review. *Acta Orthop Scand* 2001;72:308–17.
- [4] Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW. Bone cancer pain. *Ann N Y Acad Sci* 2010;1198:173–81.
- [5] Hoskin P. In Wall & Melzack's textbook of pain. 6 ed. McMahon S, Koltzenburg M, Tracey I, Turk DC, editors: Elsevier, Saunders; 2006.
- [6] Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Hartsell W; American Society for Radiation Oncology (ASTRO). Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. *Int J Radiat Oncol Biol Phys* 2011 Mar 15;79:965–76.
- [7] Bradley NM, Husted J, Sey MS, Husain AF, Sinclair E, Harris K, et al. Review of patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy. *Support Care Cancer* 2007;15:373–85.
- [8] Maher EJ. The influence of national attitudes on the use of radiotherapy in advanced and metastatic cancer, with particular reference to differences between the United Kingdom and the United States of America: implications for future studies. *Int J Radiat Oncol Biol Phys* 1991;20:1369–73.
- [9] Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. *J Clin Oncol* 2007;25:1423–36.
- [10] Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. *Clin Oncol (R Coll Radiol)* 2012;24:112–24.
- [11] Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. *Radiother Oncol* 1992;23:74–8.
- [12] Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. *Int J Radiat Oncol Biol Phys* 1998;42:161–7.
- [13] Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. *Radiother Oncol* 1999;52:101–9.
- [14] Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. *Radiother Oncol* 2006;79:278–84.
- [15] Bone pain trial working party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. *Radiother Oncol* 1999;52:111–21.
- [16] Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Int J Radiat Oncol Biol Phys* 2012;82:1730–7.
- [17] Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiother Oncol* 2002;64:275–80.
- [18] Huisman M, van den Bosch MA, Wijlemans JW, van Vulpen M, van der Linden YM, Verkoijen HM. Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. *Int J Radiat Oncol Biol Phys* 2012;84:8–14.
- [19] Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. *Lancet* 2000;355:1428–9.
- [20] Chow E, Hird A, Zhang L, Sinclair E, Danjoux C, Barnes E, et al. Change in urinary markers of osteoclast activity following palliative radiotherapy for bone metastases. *Clin Oncol (R Coll Radiol)* 2009;21:336–42.